Glasgow prognostic score may predict survival in small cell lung cancer
Click Here to Manage Email Alerts
Key takeaways:
- Patients with favorable scores achieved better outcomes after first-line therapy.
- It is unclear if results can be generalized to other cohorts of patients with small cell lung cancer.
Glasgow prognostic score appeared associated with survival among patients with small cell lung cancer treated with first-line atezolizumab plus carboplatin and etoposide, according to study results.
No biomarkers are available to predict effectiveness of first-line therapy with atezolizumab (Tecentriq, Genentech) — an anti-PD-L1 antibody — plus carboplatin and etoposide for patients with small cell lung cancer, according to study background.
Satoshi Wasamoto, MD, of the division of respiratory medicine at Saku General Hospital Advanced Care Center in Japan, and colleagues evaluated whether certain factors predicted efficacy of the regimen for patients with extensive-disease small cell lung cancer.
Those factors included Glasgow prognostic score — a cumulative measure based on C-reactive protein and albumin that indicates systemic inflammatory response — as well as BMI and neutrophil-to-lymphocyte ratio.
Researchers reviewed data from 84 patients treated at nine institutions in Japan from August 2019 to May 2021.
Investigators used Kaplan–Meier and Cox proportional hazard models to assess differences in PFS and OS.
Results showed a 72.6% (95% CI, 63-82.1) response rate, with median PFS of 5.4 months (95% CI, 4.9-5.9) and median OS of 15.4 months (95% CI, 11.4-16.8).
Glasgow prognostic score independently predicted outcomes after first-line therapy with atezolizumab plus carboplatin and etoposide.
Patients with favorable scores (0 or 1) achieved significantly longer PFS (5.8 months vs. 3.8 months; P = .0005) and OS (16.5 months vs. 8.4 months; P < .0001) than those with poor scores (2).
“This is the first analysis to evaluate the association between the [Glasgow prognostic score, neutrophil-to-lymphocyte ratio and BMI] and the treatment effectiveness of survival among patients receiving first-line atezolizumab plus carboplatin and etoposide therapy for [small cell lung cancer],” Wasamoto and colleagues wrote. “[Glasgow prognostic score] was significantly associated with the PFS and OS rates, suggesting that [it] might be useful for evaluating therapeutic outcomes in these patients.”
Additional large-scale studies are necessary to determine if the results of this analysis can be generalized to other cohorts of patients with small cell lung cancer, researchers wrote.
Collapse
Read more about
Click Here to Manage Email Alerts